Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of aminoglycoside-based antibiotic combination and protective isolation in critically ill neutropenic patients with sepsis
2019-003016-32Phase 3Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of amikacin in sepsis, neutropenia and cancer (4 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Day-90 mortality. Started Nov 2019; status: active.
02
Drugs
amikacin
03
Conditions
sepsisneutropeniacancer
Beyond the preview
Go deeper on 2019-003016-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003016-32.